This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Treatment

Authoring team

Seek expert advice.

Treatments to consider include:

In adults (1):

  • first line regimen : doxycycline 6 weeks+rifampicin 6 weeks+gentamicin 2 weeks OR doxycycline 6 weeks+gentamicin 2 weeks
  • alternative : Doxycycline 6 weeks+streptomycin 2 weeks
  • second line regimen : Doxycycline+rifampicin 6 weeks OR tetracycline 6 weeks+gentamicin/streptomycin 2 weeks
  • not recommended: Monotherapy OR <30 days of treatment OR quinolone with or without rifampicin/doxycycline
    • monotherapy is ineffective and followed by relapse after an initial clinical response

In children:

  • children aged under 8 and pregnant women cannot be treated with tetracyclines and quinolones. WHO guidelines recommend rifampicin monotherapy, while other sources recommend co-trimoxazole monotherapy or the combination of these two antibiotics (1)

Note that Brucella are intracellular organisms and relapse is likely, even after antibiotic treatment.

Brucella in milk is killed by pasteurization.

Please check the respective summary of product characteristics of drugs described and the prescribing information in the current issue of BNF.

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.